OKYO Pharma Limited (NASDAQ:OKYO) Sees Large Decline in Short Interest

OKYO Pharma Limited (NASDAQ:OKYO) was the recipient of a significant decline in short interest in February. As of February 15th, there was short interest totalling 259,200 shares, a decline of 22.1% from the January 31st total of 332,800 shares. Based on an average daily volume of 132,300 shares, the short-interest ratio is presently 2.0 days. Currently, 1.1% of the shares of the stock are sold short.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and set a $7.00 price objective on shares of OKYO Pharma in a research report on Tuesday, February 18th.

OKYO Pharma Price Performance

Shares of OKYO Pharma stock traded down $0.06 on Thursday, reaching $1.33. The stock had a trading volume of 21,203 shares, compared to its average volume of 207,826. OKYO Pharma has a fifty-two week low of $0.81 and a fifty-two week high of $1.90. The business’s 50-day moving average price is $1.12 and its two-hundred day moving average price is $1.08.

About OKYO Pharma

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.